Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention

Journal of Invasive Cardiology

Volumn 20, Issue 7, 2008, Pages 323-327

  Marmur, Jonathan D ^a   Poludasu, Shyam ^a   Feit, Alan ^a   Battala, Venkata R ^a   Cavusoglu, Erdal ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DALTEPARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; ORAL ANTIDIABETIC AGENT; WARFARIN;

ACTIVATED CLOTTING TIME; ADD ON THERAPY; ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CORONARY ARTERY THROMBOSIS; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDY; THROMBOSIS PREVENTION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD LOSS, SURGICAL; CONTROLLED CLINICAL TRIALS AS TOPIC; DALTEPARIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFUSIONS, INTRAVENOUS; MONITORING, PHYSIOLOGIC; RETROSPECTIVE STUDIES; TIME FACTORS; WHOLE BLOOD COAGULATION TIME;

EID: 48149100948     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Cohen M, Demers C, Gurfinkel EP, et al, for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events Study Group. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447.
2. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100:1593.
3. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA 2004;292:45.
4. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355:1006-1017.
5. Henry TD, Satran D, Knoxx LL, et al. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin? Am Heart J 2001;142:590-593.
6. Marmur JD, Anand SX, Bagga RS, et al. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 2003;41:394-402.
7. Cavusoglu E, Lakhani M, Marmur JD. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration. J Invasive Cardiol 2005;17: 416- 421.
8. Marmur JD, Bullock-Palmer RP, Lakhani MJ, Cavusoglu E. Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention. J Invasive Cardiol 2006;18(Suppl E):1E-13E.
9. Kereiakes DJ, Kleiman NS, Fry E, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001;141:348-352.
10. Marmur JD, Mitre CA, Barnathan E, et al. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Insights from the very early outcomes in the EPIC trial. Am Heart J 2006;152:876-881.
11. Marmur JD, Poludasu S, Agarwal A, et al. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention. J Invasive Cardiol 2006;18:521-526.
12. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991;115:256-265.
13. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863.
14. Kastrati A, Mehilli J, Schuhlen H, et al. for the Intracoronary Stenting and Antithrombotic Regimen - Rapid Early Action for Coronary Treatment study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350: 232-238.
15. Fischell TA, Attia T, Rane S, Salman W. High-dose, single-bolus eptifibatide: A safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions. J Invasive Cardiol 2006;18:487-491.
16. Natarajan MK, Velianou JL, Turpie AG, et al. A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. Am Heart J 2006;151:175.